Protein-degrading drugs use our cells' normal processes for removing old proteins, but direct them to attack specific proteins in diseased cells.

The protein KRAS, mutated in many cancers, was deemed ‘undruggable’. Now scientists are hoping to save lives with a batch of new compounds that target it.

Purdue University scientists are at work on a new cancer treatment that attacks immune system cells that feed and protect cancer cells rather than attacking them. The immunotherapy process promises to become a universal treatment for solid tumors. Thus far, the treatment has been tested and shown to work on human tumor cells in the laboratory and animal models.

The immune system detects and destroys abnormal cells, curbing the growth of many cancers. Immunotherapy works to boost the body’s immune system to target and kill cancer cells. There are many ways to accomplish this, including adaptive cell therapy, checkpoint inhibitors, vaccines, and monoclonal antibodies.

Genetic profiling of tumors—based on a sample from the tumor, a patient's blood, or both—can help clinicians determine if targeted therapies known to block the growth of certain types of tumors would be appropriate for specific patients.

While new treatments for cancer are under continuous development, researchers are increasingly using engineering principles to find wholly new strategies to combat the disease. Directions include nanoparticle drug delivery, advanced imaging tools, developing new materials to interact with cells, tissue engineering, robotic surgeries, and more. Such interdisciplinary efforts are expected to unlock new tools and therapies beyond traditional drug formulation.

Medical robots are on the verge of being able to be injected into the body, where they will be responsible for semi-autonomous behavior, such as detecting cancer cells and distributing medication. This six-minute video dives into the science of these nanorobots, which are smaller than blood cells. Applications of these nanobots could range from disease discovery and condition monitoring to tissue repair and artificial blood delivery.

Certain gene variants can affect how quickly or slowly medications are broken down in the body, affecting drug effectiveness and the risk of drugs failing. Such testing is often not covered by insurance companies though research indicates if these tests were performed for more than six drugs across the US population, avoided ailments would likely climb into the hundreds of thousands.

The therapy, originally targeting cancer, involves taking a patient's own T cells, genetically reprogramming them to recognize and attack a specific target and then infusing them back into patients. For autoimmune diseases, the therapy instead programs them to target immune cells that are causing problems, restoring immune system tolerance.

The Dana-Farber Cancer Institute provides a delightful Science Illustrated animation explaining PD-1/PD-L1 immunotherapy and how it fights cancer. Briefly, the treatment helps T-cells recognize cancerous cells that would ordinarily be "disguised" by proteins and attack. The fight is made more fair and effective by immunotherapy and similar cancer treatments.

Before cells divide, a protein called p53 can halt the cell cycle if damaged DNA is identified, preventing the fault from propagating to daughter cells. If p53 and other tumor-suppressing molecules cannot function due to mutations or other instabilities, damage can accumulate over successive generations until nothing stops cells from dividing uncontrollably, creating tumors.

BPC-157, which purportedly helps with tissue repair and muscle growth, can cause concerning side effects, including pain and swelling. TB-500, another experimental peptide, is marketed for wound healing, but it hasn't undergone any clinical human trials, and high levels of this peptide have been linked to tumor growth.

In recent years, weight loss drugs made a tremendous amount of money for Novo Nordisk and Eli Lilly. Other companies are developing new drugs to break into the market. This piece is a concise overview of companies creating and testing new drugs, how far along they are, and what Novo Nordisk and Eli Lilly are doing to compete with these emerging rivals.

CAR T-cell therapy is a type of immunotherapy, which involves strengthening the immune system to attack cancer cells. Patient T cells, which manage immune responses and are responsible for killing pathogen-infected cells, are collected and re-engineered to produce surface-level proteins called chimeric antigen receptors. These CARs, now able to bind to specific proteins on cancer cell surfaces, are multiplied into the millions and infused back into the patient.

Short for chimeric antigen receptor T-cell therapy, CAR-T Cell Therapy helps augment the body's own ability to attack cancer cells. It's a cell-based gene therapy that alters the genes in a person's T cells—which are a type of immune cell—to help them beat back cancerous growths.

Clinical data from a couple patients in 2025 indicated that one experimental CAR-T therapy called rese-cel was able to genetically reprogram T cells to eliminate certain problematic immune B cells that were causing the condition. The therapy reduced skin thickening and allowed the patients to halt using immunosuppressive medications and steroids.

A study shows trametinib and rapamycin, two drugs used for cancer treatment in humans, increased mouse lifespan when used together. The medications delayed the onset of cancer and reduced chronic inflammation, results that will be explored in future research.

Watch a board-certified sports medicine therapist detail his thinking about this synthetic peptide; he says it's "promising but unproven." He notes that this product is designed to mimic the natural protein thymosin beta-4, found in human and animal tissues, which promotes wound healing. TB-500 is classified as a research peptide for recovery, meaning it's not approved for human use and has not yet undergone rigorous human trials on its safety and efficacy.

Although no organism has ever lost all its DNA, the destroying angel mushroom contains amatoxin, which disrupts DNA transcription and is known to cause death via liver and kidney failure in three days. Doxorubicin, which tangles DNA to disrupt cellular replication, compromises a person's immune system.

Creutzfeldt-Jakob disease is currently incurable and can cause one's death within months of symptoms appearing. It involves misfolded proteins that, for some reason yet unknown to science, aren't cleared by the brain as typical and instead trigger similar proteins to misfold. These malformed major prion proteins—prion being a portmanteau of protein and infection—clump inside nerve cells, blocking signals crucial to processes ranging from speaking to organ function.